Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 1:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 184 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: AC2993 (exenatide) Clear all
Not listed Phase 4 Interventional

Evaluation of the Impact of Intensive Short-Term Drug Therapy in Patients With Type 2 Diabetes Mellitus

NCT04027023
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Diabetes mellitus Type 2 De-escalation treatment (DET)
Drug
Lead sponsor
Sciema UG
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Oct 4, 2026, 1:24 PM EDT
Completed No phase listed Observational

A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease

NCT03492580
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Cardiovascular Diseases
Interventions
Canagliflozin, Empagliflozin, Dapagliflozin, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Glucagon-like Peptide-1 (GLP-1) Agonist, Anti-hyperglycemic Agents (AHA), Thiazolidinediones (TZD), Sulfonylureas (SU), Insulin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
Not listed
Enrollment
714,582 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Titusville, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Oct 4, 2026, 1:24 PM EDT
Completed Phase 4 Interventional

Efficacy Evaluation of Different Medication Combination in Type 2 Diabetes Treatment

NCT01076842
View directory record Official record
Conditions
Diabetes Type 2
Interventions
Insulin-Levemir, Exenatide-Bayetta, Insulin-Levemir and Exenatide-Bayetta, SenseWear Pro3® armband, DexCom CGM
Drug · Device
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 90 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 27, 2011 · Synced Oct 4, 2026, 1:24 PM EDT
Completed Phase 2 Interventional Results available

Assess the Efficacy and Safety of Exenatide SR for the Prevention of Diabetes After Kidney Transplantation

NCT03961256
View directory record Official record
Conditions
Pre Diabetes
Interventions
Exenatide SR
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 28, 2022 · Synced Oct 4, 2026, 1:24 PM EDT
Not listed Phase 1Phase 2 Interventional

Proof of Concept Study in Patients With Short Bowel Syndrome

NCT04379856
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
NM-002
Drug
Lead sponsor
9 Meters Biopharma, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 20, 2020 · Synced Oct 4, 2026, 1:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Effect of ITCA 650 on the PK/PD of Oral Contraceptive in Healthy Female Subjects

NCT02641990
View directory record Official record
Conditions
Healthy Adult Premenopausal Female Volunteers
Interventions
ITCA 650 20/60 mcg/day, ITCA placebo, ITCA placebo, ITCA 650 20/60 mcg/day
Drug
Lead sponsor
Intarcia Therapeutics
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 22, 2016 · Synced Oct 4, 2026, 1:24 PM EDT
Recruiting Phase 2 Interventional

Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis

NCT07497399
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
NLY01, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 60 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 4, 2026, 1:24 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

The Effects of Exenatide (Byetta ) on Energy Expenditure and Weight Loss in Nondiabetic Obese Subjects

NCT00856609
View directory record Official record
Conditions
Weight Loss, Obesity
Interventions
Byetta (exenatide), Weight loss, Metabolic Chamber, Placebo
Drug · Behavioral · Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 55 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 4, 2019 · Synced Oct 4, 2026, 1:24 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study to Examine the Pharmacokinetics, Tolerability, Safety and Efficacy of Exenatide Once Weekly Suspension

NCT00894322
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
exenatide once weekly, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
19 Years to 75 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 18, 2015 · Synced Oct 4, 2026, 1:24 PM EDT
Completed Not applicable Interventional Results available

Effects of Exenatide on Overweight Adolescents With Prader-Willi Syndrome

NCT01444898
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
Exenatide
Drug
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
13 Years to 20 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 29, 2016 · Synced Oct 4, 2026, 1:24 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

How Glargine Insulin, Oral Diabetes Medications and Exenatide May Improve Blood Sugar Control and Weight Gain in Type 2 Diabetics

NCT00667732
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
exenatide, placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
30 Years to 70 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Rochester, Minnesota • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 6, 2013 · Synced Oct 4, 2026, 1:24 PM EDT
Not listed Phase 2Phase 3 Interventional

The Effects of Exenatide After Gastric Restriction

NCT00872378
View directory record Official record
Conditions
Morbid Obesity
Interventions
Exenatide, Placebo
Drug
Lead sponsor
Advanced Specialty Care
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Bend, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 31, 2009 · Synced Oct 4, 2026, 1:24 PM EDT
Completed Phase 4 Interventional Results available

Intravenous Exenatide in Patients With Acute Brain Injury

NCT02058940
View directory record Official record
Conditions
Brain Injuries
Interventions
Exenatide
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Oct 4, 2026, 1:24 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of the Safety and Effectiveness of LY3053102 in Participants With Type 2 Diabetes

NCT02020616
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
LY3053102, Exenatide ER, Placebo, Metformin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
21 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
5
States / cities
Orange, California • Miami, Florida • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Oct 4, 2026, 1:24 PM EDT
Completed Phase 2 Interventional

Study Examining Exenatide Long-Acting Release in Subjects With Type 2 Diabetes

NCT00103935
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
placebo, Exenatide LAR
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
7
States / cities
Walnut Creek, California • Honolulu, Hawaii • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2015 · Synced Oct 4, 2026, 1:24 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Weight Loss With Exenatide Treatment

NCT01590433
View directory record Official record
Conditions
Obesity
Interventions
Exenatide, Placebo, Dietary counseling
Drug · Behavioral
Lead sponsor
Jody Dushay
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
249 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Oct 4, 2026, 1:24 PM EDT
Completed Phase 4 Interventional

The Effect of Byetta and Symlin on Post-meal Meal Blood Sugar Levels in Children With Type 2 Diabetes

NCT00950677
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Byetta (exenatide), Symlin (pramlintide)
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
12 Years to 21 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2017 · Synced Oct 4, 2026, 1:24 PM EDT
Completed Phase 4 Interventional Results available

Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 Diabetes

NCT02455076
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Exenatide, Glargine, Rapid-acting insulin analogs
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 20, 2019 · Synced Oct 4, 2026, 1:24 PM EDT
Completed Phase 3 Interventional

Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With Metformin

NCT00039013
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
AC2993, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
16 Years to 75 Years
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
129
States / cities
Anniston, Alabama • Birmingham, Alabama • Eclectic, Alabama + 99 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2015 · Synced Oct 4, 2026, 1:24 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Pharmacology of Exenatide in Pediatric Sepsis

NCT01573806
View directory record Official record
Conditions
Septic Shock, Inflammation, Glucose Homeostasis, Organ Dysfunction, Health-related Quality of Life
Interventions
Exenatide, Exenatide vehicle
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
1 Month to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Oct 4, 2026, 1:24 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Exenatide Once Weekly for Smoking Cessation

NCT02975297
View directory record Official record
Conditions
Smoking Cessation
Interventions
Exenatide, NRT, Counseling, Placebo
Drug · Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 75 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Oct 4, 2026, 1:24 PM EDT
Active, not recruiting No phase listed Observational

Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study

NCT05220917
View directory record Official record
Conditions
Cardiovascular Events, Type2 Diabetes, Renal Disease
Interventions
SGLT2 inhibitor, DPP-4 inhibitor, GLP-1RA, 2nd generation SU
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
781,430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 4, 2026, 1:24 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria

NCT03331289
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, Exenatide, Dapagliflozin, Exenatide and Dapagliflozin
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 70 Years
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Oct 4, 2026, 1:24 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Role of Exenatide in NASH-a Pilot Study

NCT00650546
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease
Interventions
Exenatide
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 99 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
3
States / cities
Indianapolis, Indiana • Kansas City, Missouri • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Oct 4, 2026, 1:24 PM EDT